CSL Behring is 2016 'Victorian Manufacturer of the Year'

Melbourne, Australia – CSL Behring's Australian facility was last night awarded '2016 Victorian Manufacturer of the Year' in the Large Business category at the Victorian Manufacturing Hall of Fame Awards.

CSL Behring is a global leader in biotherapies and part of CSL Limited. Focused on serving patients' needs by using the latest technologies, CSL Behring develops innovative therapies that are used to treat coagulation disorders, primary immune deficiencies, hereditary angioedema, inherited respiratory disease, and neurological disorders. The company's products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent haemolytic disease of the newborn. It operates one of the largest human plasma collection networks in the world to gather the raw material to produce the biotherapies, with manufacturing capabilities in the US, Germany, Switzerland and Australia. In Victoria, CSL Behring operates two plasma product manufacturing facilities and a Biotechnology Manufacturing Facility at its 24 ha site in Broadmeadows.

As the nation's national plasma fractionator since 1953 CSL Behring has played an important role in ensuring the supply of life-saving plasma products for Australians. Recently, the Broadmeadows facility has augmented its long-standing Australian product portfolio with a major new facility that enables the processing of US-collected plasma intermediate to manufacture of the company's product 'PRIVIGEN®'. PRIVIGEN® is used as a therapy for people with immune system disorders.

The newly completed PRIVIGEN® manufacturing facility involved a five year design and construction phase.

Technical and scientific aspects were the result of international collaboration within CSL's global network and include methods of manufacture, product specifications, quality control test methods, facility and equipment requirements and training of staff.

The first batch of PRIVIGEN® was exported in December 2015 to treat patients in the United States.

"We are delighted to be Victorian Manufacturer of the Year and to showcase the potential of advanced manufacturing in Australia. With our manufacturing capabilities, we can deliver on our longstanding promise to produce and bring to market innovative biotherapies that help patients live full lives around the world," said Mr Martin Schaeren, General Manager CSL Behring Australia.

"It is particularly serendipitous for us to receive this award in 2016 as this year we are celebrating CSL's centenary and the generations of scientists, medical professionals and governments whose passion and commitment have played a role in making CSL the globally successful, innovative company it is today.

"This award is a tribute to the skilled and dedicated CSL Behring cross functional, global team of manufacturing experts, scientists and engineers who have been committed to this project for more than five years," he said.

More than 900 employees work at CSL Behring's Broadmeadows manufacturing facility, around 250 of these staff support the new PRIVIGEN® and Biotechnology Manufacturing facilities.

Over the past 5 years, CSL Behring has received strategic co-investments from the State and Federal Governments, including a grant to support the construction of the PRIVIGEN® Facility, which has helped to secure CSL's ongoing development of the biotechnology sector and advanced manufacturing in Australia.

Media Contact

Jemimah Pentland / Head of Communications, Asia Pacific / Phone: +61 412 635 483

About CSL Behring

CSL Behring is a global biotherapeutics leader which is driven by its promise to save lives. Focused on serving patients' needs by using the latest technologies, we develop and deliver innovative therapies that are used to treat coagulation disorders, primary immune deficiencies, hereditary angioedema, inherited respiratory disease, and neurological disorders. The company's products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic disease of the newborn.

CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. The parent company, CSL Limited (ASX:CSL), headquartered in Melbourne, Australia, employs more than 16,000 people with operations in more than 30 countries. For more information visit www.cslbehring.com and follow us on www.Twitter.com/CSLBehring.

About CSL

CSL is a leading global biotherapeutics company with a dynamic portfolio of life-saving innovations, including those that treat haemophilia and immune deficiencies, as well as vaccines to prevent influenza. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL — including our two businesses CSL Behring and Seqirus — operates in over 30 countries with more than 16,000 employees. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so patients can live life to the fullest.